88 research outputs found
Addressing critical knowledge gaps to improve and shorten multidrug-resistant tuberculosis treatment regimens in children
Thesis (PhD)--Stellenbosch University, 2018.ENGLISH ABSTRACT: Multidrug-resistant (MDR) tuberculosis (TB), defined as TB disease or infection caused
by Mycobacterium tuberculosis with resistance to at least both isoniazid and rifampicin,
threatens global TB control, with an estimated 490,000 incident cases of MDR-TB
globally in 2016. The burden of paediatric MDR-TB has been poorly characterized to
date. However, recent modeling studies estimate that there are approximately 26,000-
32,000 incident MDR-TB cases in children (< 15 years of age) worldwide each year.
Traditionally, treatment regimens for adults and children were constructed using a
minimum of four second-line antituberculosis drugs likely to be effective, including a
second-line injectable medication, for up to 6 months, and a total duration of treatment
of up to 18-24 months. In 2016, the World Health Organization (WHO) recommended a
shortened (9-12 month) treatment regimen, which still includes an injectable drug for
four months. In addition, the development and increasing use of the novel TB drugs
bedaquiline and delamanid, are radically altering the MDR-TB treatment landscape,
although children have lagged behind in accessing these important developments.
Treatment outcomes for adults with MDR-TB have been persistently poor, with 54%
successfully treated in 2014 both overall globally, and in South Africa. In contrast,
treatment outcomes among children with MDR-TB are generally good, with 78-90%
successfully treated under routine clinical conditions. However, current paediatric
MDR-TB treatment regimens have important limitations. These current regimens
remain long (9-18 months or more), which is costly and burdensome. There are also
frequent adverse effects, including from the second-line injectable medications
(amikacin, kanamycin, capreomycin) that cause permanent sensorineural hearing loss
in up to 24% of children treated long-term. Additionally, the injectables are mainly
given by painful daily intramuscular injections, resulting in trauma and distress for
patients, their caregivers and healthcare providers. Therefore, it is an urgent priority to
develop more optimal treatment regimens for children with MDR-TB that retain their
efficacy but are shorter, more child-friendly, are better tolerated, safer and which do not require the use of an injectable medication.
The purpose of this doctoral research was to address critical knowledge gaps in
paediatric MDR-TB treatment, with the aim of informing more effective, safer, and more
child-friendly MDR-TB treatment strategies in children. I identified critical knowledge gaps related to the pharmacokinetics, including the effects of formulation, optimal
dosing, safety, and tolerability of key second-line and novel antituberculosis drugs in
children, and completed complementary studies on ofloxacin, levofloxacin, linezolid,
amikacin and bedaquiline designed to address these knowledge gaps.
In an observational study of the pharmacokinetics and safety of ofloxacin in children
routinely treated for MDR-TB disease or exposure, exposures after a daily 20mg/kg
ofloxacin dose were well below target exposures from adults receiving the routine 800
mg dose. Ofloxacin was safe and well tolerated, with few musculoskeletal complaints or
serious adverse events. This data adds to the evidence of the safety of fluoroquinolones
in children even with long-term use, and identifies the need to revise ofloxacin
paediatric doses.
Subsequently, in this large observational study, the population pharmacokinetics of
levofloxacin among children with MDR-TB disease or exposure was characterized using
non-linear mixed effects modeling. One hundred and nine children treated with the
routinely available adult 250 mg tablet formulation of levofloxacin at daily doses of 15
mg/kg or 20 mg/kg were included. Levofloxacin’s apparent oral clearance (CL/F) was
higher than expected based on previously published data, possibly due to the
formulation studied. Simulations using the final model targeting exposures in adults
with TB receiving 750 mg of levofloxacin identified weight-banded doses that were
much higher than previously in use (18 mg/kg to nearly 40 mg/kg daily). It was
concluded that levofloxacin dosing in children should be reassessed, formulation effects
explored further, and that safety should be carefully evaluated if higher levofloxacin
doses are used.
Building on this data, I completed an evaluation of the safety of long-term levofloxacin
in children treated for MDR-TB. Among 70 children, median age 2.1 years, treated for a
median of 11.6 months, levofloxacin was generally safe and was well tolerated. There
were no Grade 4 or serious adverse events, and few musculoskeletal events. There was
no QT-interval prolongation and no association of QT interval with levofloxacin
concentration. This study supported the safety of long-term fluoroquinolone treatment
in children, and provided novel data on the QT prolonging effect of levofloxacin, which
is needed, as increasingly levofloxacin is being combined with other QT prolonging
medications.
The effects of drug formulation in pharmacokinetic studies are critically important. In a
lead-in pharmacokinetics study to the TB-CHAMP trial (phase 3 cluster randomized trial
comparing levofloxacin vs. placebo for prevention of TB in child contacts of MDR-TB
cases), 24 children had pharmacokinetic sampling with a novel dispersible tablet
formulation of levofloxacin. The levofloxacin exposures were much higher with this
novel formulation compared to those seen in the previously reported study using the
adult 250 mg levofloxacin tablet. Combining these two data sets using non-linear mixed
effects modeling identified that reduced bioavailability of the adult 250 mg tablet
formulation compared to the dispersible levofloxacin tablet was the explanation for the
substantial differences in exposures. This study highlighted the importance of
formulation considerations to paediatric pharmacokinetic studies and provided
practical weight-banded dosing guidelines for use of this formulation now becoming
available in the field.
Linezolid is a key drug with an increasingly important role in the treatment of MDR-TB
strains with additional resistance and in central nervous system TB disease. I
performed a structured review of the literature on linezolid to inform its use in children
for MDR-TB treatment and identify knowledge gaps for future research. Few children
treated with linezolid for MDR-TB were described in the literature. As in adults,
linezolid appeared to be effective but was associated with frequent adverse events.
There was no data on linezolid pharmacokinetics in children with TB. Practical interim
guidance was provided for linezolid use in children. Priority research needs identified
included studying linezolid pharmacokinetics in children with TB, characterization of its
safety with long-term use, and its optimal dose for TB in MDR-TB regimens going
forward.
Following on this review, an analysis of linezolid pharmacokinetics and safety from
children with MDR-TB was performed with data from 48 children combined from two
observational studies using non-linear mixed effects modeling. Seventeen children
received long-term linezolid and were monitored longitudinally for safety; 31 children
only contributed cross-sectional pharmacokinetic data after a single-dose of linezolid.
After accounting for the effects of weight with allometric scaling, no other covariates
significantly contributed to the model. Exposures were higher than expected, based on
previously reported data. Ten of 17 participants had a linezolid related adverse event, including five Grade 3 or 4 events; anaemia was the most common event. This first data
on linezolid pharmacokinetics in children demonstrated higher than expected
exposures and frequent, serious linezolid-related adverse events, and will inform the
use and future dosing recommendations of this increasingly important antituberculosis
medication in children.
While drug substitutions for injectable drugs are not yet available for many children,
improving the tolerability of the continued use of second-line injectable medications is
an important question to address in children. A randomized two-period crossover
study was designed to characterize the effect of co-administration of lidocaine on the
pain and pharmacokinetics of intramuscular amikacin. Children each received a dose of
amikacin with and without additional lidocaine on separate days, and were randomized
to the sequence of treatments; pain assessments and pharmacokinetic sampling were
performed on each day. Twelve children were enrolled and completed the study. The
addition of lidocaine reduced pain immediately after the injection, was safe, and did not
affect the pharmacokinetics of amikacin in children, and should be considered as a
routine policy in patients with MDR-TB receiving an injectable agent.
The novel drug bedaquiline is increasingly used globally and in South Africa for adults
with MDR-TB, and ongoing paediatric trials will characterize the pharmacokinetics,
safety and optimal dose in children. The paediatric formulation, which is being
evaluated in at least one of the ongoing paediatric trials, may not be available for
routine care for some time. In order to inform the rational use of the adult bedaquiline
formulation in young children, a randomized two-period crossover study in healthy
adult volunteers was designed. Adult bedaquiline tablets administered suspended in
water were bioequivalent to adult tablets swallowed whole. The suspended tablets
were also found to be acceptable and palatable to the majority of participants, an
important finding considering that crushing or suspending some tablets, such as the
fluoroquinolones, reduces their palatability and acceptability substantially. This data
will accelerate access to bedaquiline for young children in research and routine care.
In conclusion, this doctoral research has addressed a number of important key knowledge gaps related to more optimal paediatric MDR-TB treatment. This research
has raised a number of follow-up questions that have informed subsequent studies that will continue to advance the field towards a goal of effective, safe, shorter MDR-TB
treatment for all children.AFRIKAANSE OPSOMMING: Multimiddel-weerstandige (MMW) tuberkulose (TB), wat gedefinieër word as as TB
siekte of infeksie wat veroorsaak word deur Mycobacterium tuberculosis met
weerstandigheid teen ten minste isoniasied en rifampisien, bedreig wêreldwye TB
beheer, met ‘n geskatte 490,000 nuwe gevalle van MMW-TB wêreldwyd in 2016. Die
lading van pediatriese MMW-TB is tot op hede swak omskryf. Onlangse
modeleringstudies beraam egter dat daar elke jaar ongeveer 26,000-32,000 nuwe
MMW-TB gevalle in kinders (<15 jaar oud) wêreldwyd voorkom.
Tradisioneel was die behandelingsregimens vir volwassenes en kinders saamgestel
deur ‘n minimum van vier waarskynlik effektiewe tweede-linie antituberkulosemiddels
te gebruik, insluitend ‘n tweede-linie inspuitbare middel vir tot 6 maande en totale
behandelingsduur van tot 18-24 maande. In 2016 het die Wêreldgesondheidsorganisasie
(WGO) ‘n verkorte (9-12 maande) behandelingsregimen, wat steeds ‘n
inspuitbare middel vir 4 maande ingesluit het, aanbeveel. Hierby het die ontwikkeling
en toenemende gebruik van die nuwe TB middels, bedakwilien en delamanid, gelei tot
radikale veranderinge in die MMW-TB omgewing, alhoewel kinders in die toegang tot
hierdie belangrike ontwikkelinge agtergebly het.
Die uitkomste van behandeling van MMW-TB in volwassenes was aanhoudend swak
met 54% suksesvolle behandeling in 2014 beide algeheel globaal, sowel as in Suid-
Afrika. In teenstelling hiermee is die uitkomste van behandeling in kinders met MMWTB
oor die algemeen goed, met 78-90% suksesvolle behandeling onder roetine kliniese
sorg. Huidige pediatriese MMW-TB behandeling het egter belangrike beperkings. Die
huidige behandeling bly egter van lange duur (9-18 maande of langer) wat dit duur en
moeilik maak. Daar is ook dikwels nadelige gevolge, soos byvoorbeeld permanente
sensorineurale gehoorsverlies in tot 24% van kinders wat langtermyn behandeling
ontvang en wat deur die tweede-linie inspuitbare middels (amikasien, kanamisien,
kapreomisien) veroorsaak word. Daarby word die inspuitbare middels hoofsaaklik per
pynlike binnespierse inspuiting toegedien wat trauma en angstigheid in die pasiënt, die
versorger en die gesondheidsverskaffers veroorsaak. Daarom is dit ‘n belangrike prioriteit om meer optimale behandelingsregimens vir kinders met MMW-TB te
ontwikkel wat hulle effektiwiteit behou, van korter duur en meer kindervriendelik is,
wat beter verduur word, veiliger is en wat nie enige inspuitbare middels bevat nie.
Die oogmerk van hierdie doktorale navorsing was om kritieke kennisleemtes in die
behandeling van pediatriese MMW-TB aan te spreek, met die doel om meer effektiewe,
veiliger en meer kindervriendelike MMW-TB behandelingstrategieë in kinders toe te lig.
Ek het kritieke kennisleemtes verwant aan die farmakokinetika, insluitend die effek van
formulerings, optimale dosering, veiligheid en verdraagsaamheid van sleutel tweedelinie
en nuwe antituberkulose middels in kinders geïdentifiseer en het komplimentêre
studies oor ofloksasien, levofloksasien, linezolied, amikasien en bedakwilien ontwerp
om hierdie kennisleemtes aan te spreek.
In ‘n waarnemingstudie oor die farmakokinetika en veiligheid van ofloksasien in
kinders wat normaalweg vir MMW-TB siekte of blootstelling behandel is, was die
blootstellingsvlakke na ‘n daaglikse dosis van 20 mg/kg ofloksasien duidelik laer as die
teikenblootstellingsvlakke wat bereik word deur volwassenes wat ‘n roetine dosis van
800 mg ontvang. Ofloksasien was veilig en is goed verduur met min muskuloskeletale
klagtes of ernstige nadelige gevolge. Hierdie inligting dra by tot die bewyse dat die
fluorokwinolone veilig is in kinders selfs met langtermyn gebruik en toon die behoefte
aan om die pediatriese dosisse van ofloksasien te hersien.
Hierna, in hierdie groot waarnemingstudie, is die populasiefarmakokinetika van
levofloksasien in kinders met MMW-TB siekte of blootstelling bepaal deur die nielineêre
gemengde-effekte modeleringstegniek te gebruik. Eenhonderd-en-nege kinders
wat met die normaalweg beskikbare volwasse-formulering 250mg levofloksasien
tablette behandel is met ‘n daaglikse dosis van 15 mg/kg of 20 mg/kg, is ingesluit.
Levofloksasien se oënskynlike mondelingse opruiming (CL/F) van levofloksasien was
hoër as wat verwag was volgens vorige gepubliseerde inligting, moontlik as gevolg van
die formulering wat bestudeer is. Simulasies wat die finale model gebruik het wat
blootstellingsvlakke in volwassenes wat 750 mg levofloksasien ontvang, geteiken het,
het gewigsgebaseerde dosisse geïdentifiseer wat baie hoër is as wat voorheen gebruik is
(18 mg/kg tot byna 40 mg/kg daagliks). Daar is tot die slotsom gekom dat
levofloksasiendoserings in kinders hersien moet word, formuleringseffekte verder
ondersoek moet word en dat, as hoër doserings van levofloksasien gebruik sou word,
veiligheid versigtig nagegaan moet word.
Op grond van hierdie inligting het ek die veiligheid van die langtermyngebruik van
levofloksasien in kinders met MMW-TB bestudeer en voltooi. In 70 kinders, mediane ouderdom 2.1 jaar, wat behandel is vir ‘n mediane duur van 11.6 maande, was
levofloksasien oor die algemeen veilig en is dit goed verduur. Geen Graad 4 of ernstige
nadelige effekte het voorgekom nie en net enkele muskuloskeletale effekte het
voorgekom. Geen verlenging van QT-interval het voorgekom nie en daar was geen
verband waargeneem tussen levofloksasienkonsentrasies en QT-intervalle nie. Hierdie
studie het die veiligheid van die langtermyn-gebruik van fluorokwinoloon-behandeling
in kinders ondersteun en het nuwe inligting oor die QT-verlengingseffek van
levofloksasien verskaf wat baie nodig is, want levofloksasien word toenemend tesame
met ander QT-verlengende middels aangewend.
Die effekte van middelformulerings in farmakokinetikastudies is van kritiese belang.
Tydens ‘n inleidende farmakokinetikastudie vir die TB-CHAMP studie (fase-3 cluster
ewekansige studie wat levofloksasien met plasebo vergelyk vir die voorkoming van TB
in kinderkontakte van MMW-TB gevalle) het 24 kinders farmakokinetiese
monsterneming gehad tydens die gebruik van ‘n nuwe oplosbare tablet van
levofloksasien. Die levofloksasien blootstellingsvlakke was baie hoër met hierdie nuwe
formulering in vergelyking met dié wat in die vorige studie met die gebruik van die 250
mg volwasse tablette gevind is. Deur hierdie twee inligtingstelle te kombineer deur
gebruik te maak van die nie-lineêre gemengde-effekte modeleringstegniek, het dit
geblyk dat die verminderde biobeskikbaarheid tussen die volwasse 250 mg tablette en
die oplosbare levofloksasien tablette die rede is vir die aansienlike verskil in
blootstellingsvlakke. Hierdie studie het die belangrikheid van middelformulerings
oorwegings in pediatriese farmakokinetika beklemtoon en het praktiese gewigsgebaseerde
doseringsriglyne daargestel vir die gebruik van hierdie formulering wat nou
in die veld beskikbaar raak.
Linezolied is ‘n sleutelmiddel met ‘n toenemend belangrike rol in die behandeling van
MMW-TB stamme met bykomende weerstandigheid sowel as in sentraal senuweestelsel
TB siekte. Ek het ‘n gestruktureerde oorsig van die literatuur oor linezolied onderneem
om duidelikheid te kry oor die gebruik daarvan in kinders met MMW-TB en om
kennisleemtes vir toekomstige navorsing te identifiseer. Slegs enkele kinders wat
behandel is vir MMW-TB is in die literatuur opgeteken. Soos in die geval van
volwassenes, het linezolied effektief blyk te wees, maar was met gereelde nadelige effekte geassosieer. Daar was geen inligting oor oor die farmakokinetika van linezolied in kinders met TB beskikbaar nie. Praktiese tussentydse riglyne vir die gebruik van
linezolied in kinders is voorsien. Navorsingsprioriteite wat geïdentifiseer is, het
linezolied farmakokinetika in kinders met TB, kenmerke van linezolied se veiligheid
met langtermyn gebruik en sy optimale dosering vir TB in MMW-regimens vorentoe,
ingesluit.
Na hierdie oorsig is ‘n analise van linezolied-farmakokinetika en veiligheid in kinders
met MMW-TB gedoen met inligting verkry van 48 kinders saamgevat uit twee
waarnemingstudies deur gebruik te maak van nie-lineêre gemengde-effekte
modelering. Sewentien kinders het langtermyn linezolied ontvang en is longitudinaal
vir veiligheid opgevolg; 31 kinders het slegs deursnit farmakokinetiese inligting na ‘n
enkeldosis linezolied verskaf. Na die effek van gewig met behulp van ‘n allometriese
skaal in bereking gebring is, het geen ander medevariante betekenisvol tot die model
bygedra nie. Blootstellingsvlakke was hoër as wat verwag was in vergelyking met vorige
gerapporteerde inligting. Tien van 17 deelnemers het ‘n linezolied-verwante nadelige
effek getoon, wat vyf Graad 3 of 4 effekte ingesluit het; anemie was die mees algemene
effek. Hierdie eerste inligting oor linezolied-farmakokinetika in kinders het hoër as
verwagte blootstellingsvlakke en gereelde, ernstige linezolied-verwante nadelige
effekte aangetoon; dit sal die gebruik en toekomstige doseringsaanbevelings van hierdie
toenemend-belangrike antituberkulose middel toelig.
Terwyl middelvervangings vir die inspuitbare middels vir baie kinders nog nie
beskikbaar is nie, is dit belangrik om die verbeterde verduring van die voortgesette
gebruik van die tweede-linie inspuitbare middels in kinders aan te spreek. ‘n
Ewekansige twee-periode oorkruis-studie is ontwerp om die effek van mede-toediening
van lidokaïen op die pyn en farmakokinetika van binnespierse amikasien te bepaal.
Kinders het elk ‘n dosis van amikasien met en sonder addisionele lidokaïen op aparte
dae ontvang en was ewekansig vir die volgorde van toediening ingedeel; pynevaluering
en monsterneming vir farmakokinetika is op beide dae uitgevoer. Twaalf kinders is
ingesluit en almal het die studie voltooi. Die toevoeging van lidokaïen het die pyn
onmiddelik na die toediening van die inspuiting verlig, was veilig, het nie die
farmakokinetika van amikasien beïnvloed nie en behoort as roetine beleid in pasiënte
met MMW-TB wat inspuitbare middels ontvang, oorweeg te word.
Die nuwe middel bedakwilien word toenemend wêreldwyd en in Suid-Afrika vir die
behandeling van volwassenes mt MMW-TB gebruik en voortgesette pediatriese studies
sal die farmakokinetika, veiligheid en optimale dosering in kinders toelig. Die
pediatriese formulering wat in ten minste een van die voortgesette studies evalueer
word, sal moontlik nie binnekort vir roetinegebruik beskikbaar wees nie. Om die
rasionele gebruik van die volwasse bedakwilienformulering in jong kinders toe te lig, is
‘n ewekansige twee-periode oorkruis-studie in gesonde volwasse vrywilligers ontwerp.
Volwasse bedakwilien-tablette toegedien opgelos in water was bioekwivalent aan
volwasse tablette wat heel ingesluk is. Die opgeloste tablette was ook aanvaarbaar en
smaakaanvaarbaar vir die meerderheid van die deelnemers wat ‘n belangrike bevinding
is as inaggeneem word dat die fyndruk en oplos van sommige tablette, soos
byvoorbeeld die fluorokwinolone, die smaak en aanvaarbaarheid aansienlik verminder.
Hierdie inligting sal toegang tot bedakwilien vir jong kinders in navorsing en in
algemene sorg bespoedig. Ten slotte het hierdie doktorale navorsing ‘n aantal belangrike kennisleemtes
aangespreek in verband met die meer optimale behandeling van MMW-TB in kind
Acceptability of a novel levofloxacin dispersible tablet formulation in young children exposed to multidrug-resistant tuberculosis
Levofloxacin is used for the treatment and prevention of multidrug-resistant tuberculosis in children, but current adult formulations are poorly palatable. A questionnaire administered to caregivers of 27 children taking a novel 100 mg dispersible taste-masked levofloxacin tablet found the new formulation to be more palatable (69%) and easier to prepare (81%) than the adult formulation. This formulation may assist children to better adhere to anti-tuberculous therapy
Recommended from our members
Coronavirus disease 2019 (COVID-19) pharmacologic treatments for children : research priorities and approach to pediatric studies
CITATION: Garcia-Prats, A. J. et al. 2021. Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. Clinical infectious diseases, 72(6):1067–1073. doi:10.1093/cid/ciaa885The original publication is available at https://academic.oup.com/cid/Clinical trials of pharmacologic treatments of coronavirus disease 2019 (COVID-19) are being rapidly designed and implemented in adults. Children are often not considered during development of novel treatments for infectious diseases until very late. Although children appear to have a lower risk compared with adults of severe COVID-19 disease, a substantial number of children globally will benefit from pharmacologic treatments. It will be reasonable to extrapolate efficacy of most treatments from adult trials to children. Pediatric trials should focus on characterizing a treatment’s pharmacokinetics, optimal dose, and safety across the age spectrum. These trials should use an adaptive design to efficiently add or remove arms in what will be a rapidly evolving treatment landscape, and should involve a large number of sites across the globe in a collaborative effort to facilitate efficient implementation. All stakeholders must commit to equitable access to any effective, safe treatment for children everywhere.https://academic.oup.com/cid/article/72/6/1067/5864500?login=truePublishers versio
Willingness to take multidrug-resistant tuberculosis (MDR-TB) preventive therapy among adult and adolescent household contacts of MDR-TB index cases : an international multisite cross-sectional study
CITATION: Suryavanshi, N. et al. 2020. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clinical Infectious Diseases, 70(3): 436–445. doi:10.1093/cid/ciz254The original publication is available at https://academic.oup.com/cid/Background. Household contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent disease. There is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of TB disease. Methods. In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) index cases from 16 clinical research sites in 8 countries, enrollees were interviewed to assess willingness to take a hypothetical, newly developed MDR TPT if offered. To identify factors associated with willingness to take MDR TPT, a marginal logistic model was fitted using generalized estimating equations to account for household-level clustering. Results. From 278 MDR-TB/RR-TB index case households, 743 HHCs were enrolled; the median age of HHCs was 33 (interquartile range, 22-49) years, and 62% were women. HHC willingness to take hypothetical MDR TPT was high (79%) and remained high even with the potential for mild side effects (70%). Increased willingness was significantly associated with current employment or schooling (adjusted odds ratio [aOR], 1.83 [95% confidence interval {CI}, 1.07-3.13]), appropriate TB-related knowledge (aOR, 2.22 [95% CI, 1.23-3.99]), confidence in taking MDR TPT (aOR, 7.16 [95% CI, 3.33-15.42]), and being comfortable telling others about taking MDR TPT (aOR, 2.29 [95% CI, 1.29-4.06]). Conclusions. The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MDR TPT provides important evidence for the potential uptake of effective MDR TPT when implemented. Identified HHC-level variables associated with willingness may inform education and counseling efforts to increase HHC confidence in and uptake of MDR TPT.https://academic.oup.com/cid/article/70/3/436/5421246?login=truePublishers versio
Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease
CITATION: Gupta, A. et al. 2020. Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clinical infectious diseases, 70(3): 425–435. doi:10.1093/cid/ciz235The original publication is available at https://academic.oup.com/cid/Background: We assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts (HHCs) to inform the development of an interventional clinical trial.
Methods: We conducted a cross-sectional study of adult MDR-TB cases and their HHCs in 8 countries with high TB burdens. HHCs underwent symptom screenings, chest radiographies, sputum TB bacteriologies, TB infection (TBI) testing (tuberculin skin test [TST] and interferon gamma release assay [IGRA]), and human immunodeficiency virus (HIV) testing.
Results: From October 2015 to April 2016, 1016 HHCs from 284 MDR-TB cases were enrolled. At diagnosis, 69% of MDR-TB cases were positive for acid-fast bacilli sputum smears and 43% had cavitary disease; at study entry, 35% remained smear positive after a median MDR-TB treatment duration of 8.8 weeks. There were 9 HHCs that were diagnosed with TB prior to entry and excluded. Of the remaining 1007 HHCs, 41% were male and the median age was 25 years. There were 121 (12%) HHCs that had new cases of TB identified: 17 (2%) were confirmed, 33 (3%) probable, and 71 (7%) possible TB cases. The TBI prevalence (defined as either TST or IGRA positivity) was 72% and varied by age, test used, and country. Of 1007 HHCs, 775 (77%) were considered high-risk per these mutually exclusive groups: 102 (10%) were aged <5 years; 63 (6%) were aged ≥5 and were infected with HIV; and 610 (61%) were aged ≥5 years, were negative for HIV or had an unknown HIV status, and were TBI positive. Only 21 (2%) HHCs were on preventive therapy.
Conclusions: The majority of HHCs in these high-burden countries were at high risk of TB disease and infection, yet few were receiving routine preventive therapy. Trials of novel, preventive therapies are urgently needed to inform treatment policy and practice.https://academic.oup.com/cid/article/70/3/425/5426963?login=truePublishers versio
Treatment outcomes in global systematic review and patient meta-analysis of children with extensively drug-resistant tuberculosis
Extensively drug-resistant tuberculosis (XDR TB) has extremely poor treatment outcomes in adults. Limited data are available for children. We report on clinical manifestations, treatment, and outcomes for 37 children (<15 years of age) with bacteriologically confirmed XDR TB in 11 countries. These patients were managed during 1999–2013. For the 37 children, median age was 11 years, 32 (87%) had pulmonary TB, and 29 had a recorded HIV status; 7 (24%) were infected with HIV. Median treatment duration was 7.0 months for the intensive phase and 12.2 months for the continuation phase. Thirty (81%) children had favorable treatment outcomes. Four (11%) died, 1 (3%) failed treatment, and 2 (5%) did not complete treatment. We found a high proportion of favorable treatment outcomes among children, with mortality rates markedly lower than for adults. Regimens and duration of treatment varied considerably. Evaluation of new regimens in children is required
Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis.
CAPRISA, 2018.Abstract available in pdf
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)
Background
Multidrug-resistant (MDR) tuberculosis (TB) presents a challenge for global TB control. Treating individuals with MDR-TB infection to prevent progression to disease could be an effective public health strategy. Young children are at high risk of developing TB disease following infection and are commonly infected by an adult in their household. Identifying young children with household exposure to MDR-TB and providing them with MDR-TB preventive therapy could reduce the risk of disease progression. To date, no trials of MDR-TB preventive therapy have been completed and World Health Organization guidelines suggest close observation with no active treatment.
Methods
The tuberculosis child multidrug-resistant preventive therapy (TB-CHAMP) trial is a phase III cluster randomised placebo-controlled trial to assess the efficacy of levofloxacin in young child contacts of MDR-TB cases. The trial is taking place at three sites in South Africa where adults with MDR-TB are identified. If a child aged < 5 years lives in their household, we assess the adult index case, screen all household members for TB disease and evaluate any child aged < 5 years for trial eligibility. Eligible children are randomised by household to receive daily levofloxacin (15–20 mg/kg) or matching placebo for six months. Children are closely monitored for disease development, drug tolerability and adverse events. The primary endpoint is incident TB disease or TB death by one year after recruitment. We will enrol 1556 children from approximately 778 households with an average of two eligible children per household. Recruitment will run for 18–24 months with all children followed for 18 months after treatment. Qualitative and health economic evaluations are embedded in the trial.
Discussion
If the TB-CHAMP trial demonstrates that levofloxacin is effective in preventing TB disease in young children who have been exposed to MDR-TB and that it is safe, well tolerated, acceptable and cost-effective, we would expect that that this intervention would rapidly transfer into policy.
Trial registration
ISRCTN Registry, ISRCTN92634082. Registered on 31 March 2016
The DUNE Far Detector Interim Design Report, Volume 3: Dual-Phase Module
The DUNE IDR describes the proposed physics program and technical designs of the DUNE far detector modules in preparation for the full TDR to be published in 2019. It is intended as an intermediate milestone on the path to a full TDR, justifying the technical choices that flow down from the high-level physics goals through requirements at all levels of the Project. These design choices will enable the DUNE experiment to make the ground-breaking discoveries that will help to answer fundamental physics questions. Volume 3 describes the dual-phase module's subsystems, the technical coordination required for its design, construction, installation, and integration, and its organizational structure
- …